Talk:Philip Morris International/Archives/2020

Corporate headquarters
Hi all. | Recent edits made November 4th changed PMI's headquarters to Neuchatel, Switzerland. This change is not correct, though likely made in good faith considering we do not operate there. PMI's headquarters are in New York as the original text indicated. Would anyone have a minute to change it back? I have a COI for this page. Thank you! Sarah at PMI (talk) 09:08, 8 November 2019 (UTC)
 * I fixed that. QuackGuru ( talk ) 17:54, 30 May 2020 (UTC)

New source for Research section
New source for Philip Morris International section regarding the Foundation for a Smoke-Free World. QuackGuru ( talk ) 17:54, 30 May 2020 (UTC)
 * It appears you added some text based on this source in this edit. The purpose of your talk page message is unclear. -- Beland (talk) 06:40, 31 May 2020 (UTC)
 * At the time I started this thread I did not add the source to the article. It was to bring attention to a source that can be used for the article. QuackGuru ( talk ) 14:05, 31 May 2020 (UTC)

New info proposed for History>Later Development and/or Research
Hi All. Per this press release from the U.S. FDA dated July 7, the FDA has authorized the marketing of the IQOS tobacco heating system as a modified risk tobacco product (MRTP) with Reduced Exposure information. Relevant references and more information: FDA Press Release. TPL reports with more info. In their press release, the FDA states: On a separate note, the Board of Directors is currently out of date compared to its reference source, where Harold Brown, Massimo Ferragamo, and Stephen M. Wolf are no longer shown, with no new additions at this time. As some of you know, I have a conflict of interest with this page and so will not make any edits myself. Cheers, Sarah at PMI (talk) 09:05, 24 July 2020 (UTC)
 * "This marks the second set of products ever to be authorized as MRTPs and the first tobacco products to receive “exposure modification” orders, which permits the marketing of a product as containing a reduced level of or presenting a reduced exposure to a substance or as being free of a substance when the issuance of the order is expected to benefit the health of the population" in the U.S.
 * "After reviewing the available scientific evidence, public comments and recommendations from the Tobacco Products Scientific Advisory Committee, the FDA determined that the evidence did not support issuing risk modification orders at this time but that it did support issuing exposure modification orders for these products. This determination included a finding that issuance of the exposure modifications orders is expected to benefit the health of the population as a whole."